Harvard Bioscience Expects $22.5M-$24.5M Q4 Revenue Amid Two-Year High Backlog and Expanded Product Rollouts

Harvard Bioscience expects Q4 revenue to be between $22.5M and $24.5M, with a two-year high backlog. The company has made operational progress and improved key areas, reporting Q3 revenue of $20.6M, which was at the high end of guidance and a slight sequential increase. The company is expanding product rollouts and distribution.